

Omico's

Cancer Screening Program

Understanding how comprehensive genomic profiling can potentially match you to targeted therapy for your cancer

Cancer
meets its match



Omico.

What is genomic profiling and does it matter?

Cancer can be as unique as an individual fingerprint. Genomic profiling makes it possible to identify your cancer's "fingerprint" - that is, what are the specific genetic features that make up your tumour and what is driving it to grow? Knowing this information can help your doctor find treatment options that target your specific cancer's features. This can mean more effective treatment and reduced treatment side effects.

Once your cancer is advanced, it is important to have genomic profiling early in this stage so you and your doctor have more information to help identify potential matches to precision treatments that can target your cancer.



Genomic profiling is important because it can help you to be matched to a personalised treatment, tailored to the profile of your individual cancer.

Using the changes in your cancer genes or fingerprint to find the best (most precise) treatment for your cancer, is called *precision oncology*.

What is comprehensive genomic profiling?

One type of genomic or molecular profiling for your cancer is called **comprehensive genomic profiling (CGP)**. It takes a very close look at your cancer, looking for changes in over 500 genes. The changes in genes are part of your cancer fingerprint and are called biomarkers. Comprehensive genomic profiling gives a detailed picture of your cancer, opening the door to more personalised and effective treatment options.

How can I access genomic profiling of my cancer in Australia?

Omico (The Australian Genomic Cancer Medicine Centre) is conducting a national initiative to provide free access to comprehensive genomic profiling for 23,000 Australians who have advanced or incurable cancer or an earlier diagnosis of a cancer that has a poor prognosis (i.e., the cancer has a low chance of being cured or controlled by treatment). Omico has received funding from the Australian Government, NSW Government and other private companies involved in cancer care to enable this.

Omico provides comprehensive genomic profiling of cancer:

- **free** to patients who have advanced, incurable or an earlier diagnosis of a cancer that has a poor prognosis.
- needs your **cancer doctor** (oncologist) to refer you to Omico.

The Omico Cancer Screening Program (CaSP)

Omico provides free comprehensive genomic profiling (CGP) for people in Australia with advanced, incurable or an earlier diagnosis of a cancer that has poor prognosis, through its Cancer Screening Program called CaSP.

If your cancer doctor refers you to CaSP, here's what you can expect:



The Omico CaSP study staff will contact you to guide you through the consent process. They'll collect your consent, help organise blood tests, and ask you to fill out a questionnaire.

We will request a piece of your cancer tissue, collected during a previous procedure(s) (a biopsy or a piece removed through surgery), from a pathology laboratory, and send it to an accredited sequencing laboratory (organised by the Omico CaSP team).

Your cancer tissue sample will undergo comprehensive genomic profiling at the accredited sequencing laboratory. It will be analysed to identify biomarkers and gene changes.

Omico's team of experts, known as the Molecular Oncology Board (MOB), will review the results. The MOB will see if any biomarkers or gene changes in your cancer fingerprint match with a clinical trial or other treatment designed to target your specific cancer.

The results of your CGP and the MOB report will be sent to your referring doctor, who will discuss the results and treatment options with you. This will include any potential matches to targeted treatments and/or clinical trials. Your referring doctor will arrange access to the treatment and/or clinical trial that you agree on.

Every three months the Omico CaSP team will contact you (by email) and ask you to fill out a questionnaire about how you are feeling and coping with daily activities.

How long does this all take?

It typically takes 8–10 weeks from when you have consented to participate in CaSP for your referring doctor to receive the comprehensive genomic profiling (CGP) and Molecular Oncology Board (MOB) reports. In urgent cases, as notified to the Omico CaSP team by your referring doctor, your results will usually be provided in 5–6 weeks.

How could I be matched to (or access) targeted treatments for my cancer?

The first step is to have genomic profiling, ideally **comprehensive genomic profiling**, so that you and your doctor have as much information as possible about your cancer's "fingerprint" or features. With this information, your doctor can identify the treatments that might be the best match for you.

The newest precision oncology treatments are almost always tested in clinical trials before they become widely available.

Clinical trials can be a positive step towards getting access to potentially ground-breaking treatments tailored to your cancer's fingerprint. Your safety and wellbeing are a priority to the researchers who run clinical trials. Everyone enrolled on a clinical trial gets the treatment being tested or the current standard of care treatment that they would normally get outside the clinical trial. There is no placebo or non-treatment option used in cancer clinical trials. Being on a clinical trial also means that your health and wellbeing is closely monitored by a medical team throughout the trial.

Not everyone referred to CaSP for genomic profiling will get a "fingerprint" result identifying a matching precision treatment. Sometimes, even if a precision treatment is identified there may be no clinical trial in Australia or the potential treatment may not be available. You and your doctor can discuss which treatment options might be best for you.

If a clinical trial with a matching precision treatment starts in Australia after your doctor gets your results and report, Omico will contact your referring doctor with the information.



Being part of a clinical trial offers the opportunity to receive close medical care and potentially ground-breaking therapies that could lead to improved outcomes.


If you have advanced, incurable or an earlier diagnosis of a cancer that has a poor prognosis, talk to your cancer doctor (oncologist) about **accessing the FREE comprehensive genomic profiling provided by Omico**

Ask your cancer doctor (oncologist) about comprehensive genomic profiling through Omico

- You may like to share this brochure with your oncologist to help discuss your eligibility.
- We suggest you share this with your support person who attends the oncologist appointment with you. It may be helpful to note down your questions so your support person can also listen and be part of the conversation.
- You may also contact the Cancer Screening Program (CaSP) team at Omico by emailing casp@omico.org.au or call **1800 954 350** if you have further questions.

Summary

Omico provides free comprehensive genomic profiling for people with advanced, incurable or an earlier diagnosis of a cancer that has a poor prognosis in Australia through CaSP. Genomic profiling helps to identify the specific genetic features of your tumour (your cancer's "fingerprint") and what is driving it to grow. With this information, your cancer may be matched to existing treatments or clinical trials researching innovative new treatments.



For more information

Learn more about Omico, comprehensive genomic profiling and the pathways to trials and treatments it could lead to.

Visit omico.com.au/patients-and-families/ or scan the QR code.

T. 1800 954 350
E. contact@omico.org.au

© Copyright 2024. Australian Genomic Cancer Medicine Centre Ltd, trading as Omico, is a not for profit company limited by guarantee. Hilmer Building (E10), Union Rd, UNSW, Kensington, NSW, 2052.

